PTC Therapeutics, Inc. (PTCT) announced that the European Commission (EC) has decided against adopting the Committee for Medicinal Products for Human Use’s (CHMP) negative opinion of January 2024 on the annual renewal of the conditional marketing authorization of Translarna (ataluren). Translarna is a protein restoration therapy designed to enable the formation of a functioning protein in patients with genetic disorders caused by a nonsense mutation. Following the decision, the EC has returned the opinion t ...